Alzheimer’s Disease and Parkinson’s Disease are the most common cause of dementia and movement disorders in the aging population. Over 20 million are affected worldwide and in the year 2025 it is expected that the number will double. The estimated costs for medical care for patients with Alzheimer’s Disease and Parkinson’s Disease in the US has an annual cost in excess of 50 billion dollars. Most current treatments are symptomatic and to date no cure is available. Therefore, it is critical to develop new and more rational treatments that will slow or prevent the progression.
Neurodegeneration in these disorders is proposed to result from the progressive accumulation of abnormal protein aggregates. The toxic aggregates are known as oligomers, these are globular arrays that penetrate the cell membranes and impair neuronal communication and functioning. While in AD the oligomers are composed of amyloid-β protein, in PD they are composed of alpha-synuclein.
At Neuropore Therapies we have developed, tested and patented compounds capable of interfering with the development of the toxic amyloid-β and alpha-synuclein aggregates. We have peptidomimetic and organic small molecules that interfere at various stages of the process of toxic conversion and oligomerization.